In contrast, cancer cells in the low expression group showed stronger associations with M1 and CD8+ effector T cells through interactions mediated by CXCL8−CXCR2, TNFSF10−TNFRSF10B, and IFNG−IFNGR2, potentially leading to higher immunotherapy sensitivity. This evidence concerns the gene CD8A and cancer.